Ampio Pharmaceuticals, Inc. (AMPE)
| Previous close | 0.2420 |
| Open | 0.2300 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 800 |
| Day's range | 0.3010 - 0.5100 |
| 52-week range | 0.2200 - 8.2000 |
| Volume | |
| Avg. volume | 68,595 |
| Market cap | 563,218 |
| Beta (5Y monthly) | 1.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.6600 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAmpio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going conc
- PR Newswire
Ampio Announces Voluntary Delisting and SEC Deregistration
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").
- PR Newswire
Ampio Provides Update on Results from Pre-IND Enabling Studies
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity. Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission w
